Back to Search Start Over

HDAC inhibitors in experimental liver and kidney fibrosis.

Authors :
Van Beneden K
Mannaerts I
Pauwels M
Van den Branden C
van Grunsven LA
Source :
Fibrogenesis & tissue repair [Fibrogenesis Tissue Repair] 2013 Jan 02; Vol. 6 (1), pp. 1. Date of Electronic Publication: 2013 Jan 02.
Publication Year :
2013

Abstract

Histone deacetylase (HDAC) inhibitors have been extensively studied in experimental models of cancer, where their inhibition of deacetylation has been proven to regulate cell survival, proliferation, differentiation and apoptosis. This in turn has led to the use of a variety of HDAC inhibitors in clinical trials. In recent years the applicability of HDAC inhibitors in other areas of disease has been explored, including the treatment of fibrotic disorders. Impaired wound healing involves the continuous deposition and cross-linking of extracellular matrix governed by myofibroblasts leading to diseases such as liver and kidney fibrosis; both diseases have high unmet medical needs which are a burden on health budgets worldwide. We provide an overview of the potential use of HDAC inhibitors against liver and kidney fibrosis using the current understanding of these inhibitors in experimental animal models and in vitro models of fibrosis.

Details

Language :
English
ISSN :
1755-1536
Volume :
6
Issue :
1
Database :
MEDLINE
Journal :
Fibrogenesis & tissue repair
Publication Type :
Academic Journal
Accession number :
23281659
Full Text :
https://doi.org/10.1186/1755-1536-6-1